Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine for cancer patients, at ASCO

SAN DIEGO, June 2, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the acceptance of seven key oncology research abstracts authored in collaboration with Illumina at the American Society of Clinical…

Click here to view original post